NCT01806051 - A Pilot Study on Diurnal Variation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Phenylketonuria (PKU)

Interventions

DRUG

Kuvan

Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.

Trial Locations (1)

90027

Children's Hospital Los Angeles, Los Angeles